Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study

Study limitation reported by the research below: “COVID-19 was the second most common TEAE (37.0%), heavily influenced by pandemic timing; infection rate comparisons to ASCLEPIOS should be interpreted cautiously.”